Polyomavirus middle T antigen does not overcome p53-mediated G 1 arrest in mouse embryo fibroblasts. Middle T antigen still associates with the signaling molecules phosphatidylinositol 3-kinase and SHC and activates the transcriptional activity of c-Myc and AP1 in p53-arrested cells. Examination of cell cycle regulatory proteins indicated that p53 does not interfere with these mitogenic signals but acts later in the G 1 phase of the cell cycle.
Middle T antigen (MT) is the major oncoprotein of polyomavirus (36) . It is necessary and in many cases sufficient for transformation of established cells and for induction of tumors in mice (12, 28, 29, 37) . MT interacts with several cellular proteins including phosphatidylinositol 3-kinase (PI3K) (34, 39) , SHC (3, 5) , and phospholipase C-␥ (33) . These associations activate distinct, though interactive, signaling cascades and result in induction of transcription of the early-response genes jun, fos, and myc (13, 27, 30, 35, 41) . Overall, MT activates multiple mitogenic signals, and it is through the constitutive activation of these signals that MT transforms cells (2, 17) .
The p53 tumor suppressor protein plays a critical role in suppressing cell proliferation and neoplastic transformation (20) . Inactivation of the p53 gene frequently occurs during the development of mouse and human neoplasia (8, 16) . Wild-type p53 is thought to suppress oncogene-mediated transformation through its ability to induce growth arrest and/or activate apoptosis (1) . p53 arrests the growth of cells in the G 1 phase of the cell cycle by inducing the expression of p21/WAF1, which inhibits G 1 cdk activity and prevents the phosphorylation of RB proteins (4, 9, 14, 40) .
In a previous study, we demonstrated that MT expression does not overcome p53-mediated growth arrest (7) . Cell lines for that study were generated by transfecting a temperaturesensitive p53 gene (10, 23) into mouse embryo fibroblasts derived from a p53-null animal (15) (M/tsp53). Other laboratories have characterized the temperature-sensitive p53 gene (pLTRp53cGval135) and have shown that at 37°C the protein is expressed in a mutant conformation and that at 32°C it is expressed in a functionally wild-type conformation that arrests cell growth in the G 1 /G 0 phase (22, 23) . When MT was introduced into M/tsp53 cells (M/tsp53/MT) and cultured at the permissive temperature of 32°C, M/tsp53/MT cells did not proliferate. Cell cycle analysis of M/tsp53/MT cells cultured at 32°C indicated that approximately 70% of the cells were arrested in G 1 /G 0 phase and only 10% were in the S phase of the cell cycle (7). Additionally, there was no indication that expression of MT in the p53-arrested cells induced apoptosis. Sub-G 1 /G 0 DNA fragments were not detected by fluorescenceactivated cell sorting analysis, nor were floating, dead cells observed in the cultures incubated at 32°C (7). These results indicated that expression of MT does not override the p53-mediated growth arrest or induce an apoptotic response.
In this report, we examined the mitogenic signals activated by MT in these cells to assess whether p53 was interfering directly with MT function. To determine if p53 interferes with the initial events of MT signaling, we examined whether MT associated with pp60 c-src and was phosphorylated on tyrosine residues in p53 growth-arrested cells. Cell extracts were prepared from M/puro (expressing only drug resistance), M/tsp53, and M/tsp53/MT cells after culture at 37 or 32°C for 24 h. Protein kinase assays were carried out by incubation of immunoprecipitated MT with [␥-
32 P]ATP. The top panel of Fig. 1A shows proteins in the immune complex that were phosphorylated. MT-associated kinase activity was not detected in cells lacking MT (M/puro and M/tsp53). In extracts from M/tsp53/MT cells cultured at either 37 or 32°C, proteins of 55, 70, and 85 kDa were phosphorylated. The molecular masses of 55 and 85 kDa correspond to those of MT and the regulatory subunit of PI3K. To further substantiate that MT is associated with tyrosine kinase activity and becomes phosphorylated, blots of total-cell lysates were probed with antibodies to MT and antiphosphotyrosine. We found that MT comigrates with a phosphotyrosine-containing protein in cells cultured at either temperature (bottom panel of Fig. 1A ). These results suggest that MT associates with and activates pp60 c-src tyrosine kinase in cells expressing functionally wild-type p53. In addition, MT is phosphorylated on tyrosine in cells expressing both wild-type and mutant p53.
To determine whether MT associates with the signaling molecules PI3K and SHC through its tyrosine-phosphorylated residues, we immunoprecipitated MT from cells cultured at 37 and 32°C and analyzed the associated proteins by Western blotting. Western blots were probed with antibodies to SHC and the 85-kDa subunit of PI3K (Fig. 1B) . Approximately equivalent amounts of PI3K and SHC coprecipitated with MT from cells cultured at both temperatures (Fig. 1B, left) . Similar amounts of PI3K and SHC are present in cells expressing mutant or wild-type p53 with and without MT (Fig. 1B, right) . These results indicate that the association of signaling molecules with MT is not disrupted or diminished by expression of functionally wild-type p53.
The activities of several transcription factors are stimulated by the signaling pathways activated by MT (25, 27, 30, 32, 38, 41) . To determine if the MT-activated transcription still occurs in the presence of wild-type p53, we measured the activities of several transcription factors in the p53-arrested cells. Luciferase reporter plasmids that contain multiple Myc, TPA response element (TRE), or cyclic AMP response element (CRE) sites upstream of a minimal promoter were transiently transfected into each cell line. AP1 transcription factors, composed of Jun-Fos heterodimers or jun homodimers, bind to the TRE site, while CREB/ATF transcription factors bind to CRE sites (18) . Although TRE and CRE sites are similar, TREcontaining promoters are activated by tyrosine kinase pathways and CRE-containing promoters respond to activation of the protein kinase A pathway (18) . The vector with only the minimal promoter and luciferase gene was also transfected into cells to determine the activity of the promoter without the addition of transcription factor binding sites. In addition, a plasmid with the ␤-actin promoter driving ␤-galactosidase was cotransfected to control for transfection efficiency.
Reporter plasmids were transfected into M/tsp53 and M/tsp53/MT cells that had been cultured in 10% serum at 37°C. After transfection, the cells were cultured in low serum (0.5%) at 37°C overnight. Wild-type p53 was induced and cell growth was arrested by incubation at 32°C for 48 h before harvesting the cell extract. Overexpression of wild-type p53 blocks cell cycle progression in the G 1 phase of the cell cycle (22, 23) . We examined the level of cell cycle regulatory proteins expressed in p53 growtharrested cells and after release from this growth arrest in order to estimate the point in G 1 /G 0 where wild-type p53 induces the block in cell cycle progression (Fig. 3) . Both M/tsp53 and M/tsp53/MT cells were cultured at 32°C for 24 h to arrest growth and then returned to 37°C to release the cells from the We conclude from this study that the mitogenic pathways activated by middle T antigen are insufficient to overcome the growth-suppressive function of wild-type p53. The data suggest that p53 does not act directly on any of the signal transduction pathways activated by middle T antigen but rather acts later in the G 1 phase of the cell cycle and can block the MT-activated mitogenic signals. These signal transduction pathways are similar to those activated by serum factors and tyrosine kinase receptors (17) . Constitutive activation of these receptors overcomes a major control point which appears to operate early in G 1 and which allows cells to exit the cell cycle and enter a nonproliferative state, G 0 (26) . Wild-type p53 appears to act later in G 1 at a second control point immediately prior to RB phosphorylation, referred to as the restriction or R point. Previous studies have suggested that growth suppression by wildtype p53 occurs near the R point in late G 1 (21) . Our results further support this conclusion and suggest that stimulation of early events in G 1 is unable to overcome p53-mediated growth arrest. Thus, we speculate that the p53/RB-mediated G 1 checkpoint is dominant over oncogene-activated G 0 to G 1 mitogenic pathways.
Transforming viruses have evolved common strategies to stimulate host cell proliferation; simian virus 40, adenovirus, and human papillomavirus inactivate the tumor suppressor genes p53 and RB (24) , while bovine papillomavirus and Epstein-Barr virus activate cellular growth factor signaling pathways (6) . Polyomavirus is unique in that it combines two different strategies to overcome G 1 checkpoints. MT activates mitogenic signaling pathways, and large T antigen inactivates tumor suppressor proteins, and the cooperation of both proteins is required to transform primary cells (19, 29) and induce a full tumor profile in mice (11, 12) . This work was supported by Public Health Service grant CA63111 from the National Cancer Institute.
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